Name: Lumbrukinase powder
Brand: Joyous Pellets Supplement raw materials, cosmetic ingredients, weight
Availability: InStock
Rating: 5 (1 reviews)

Lumbrukinase is a group of proteolytic enzymes (acidic proteins) extracted from special earthworms. Lumbrukinase is an anti-thrombotic drug. Lumbrukinase can also be used for ischemic cardiovascular and cerebrovascular diseases, which can improve symptoms and prevent the progression of the disease.

Product Name

Lumbrukinase

Appearance

white powder

Specification

98%

CAS No

556743-18-1

Molecular Formula

C12H15N3O2S

Package

25kg cardboard drum

GET A QUOTE

Add to Quote List リストを閲覧する

Desciption

Product information
What is Lumbrukinase Powder?
In 1982, Japan discovered urokinase-like protease in the intestines and body fluids of earthworms. In 1984, fibrinolytic enzyme, or lumbrokinase, was isolated and purified from artificially raised Eisenia worms in China. It is an acidic protein with a molecular weight of 16,000 to 45,000 D. It can directly degrade fibrin in the blood under physiological conditions and Activates plasminogen into plasmin to accelerate the dissolution of thrombus. Animal experiments show that it also has the effect of inhibiting platelet adhesion and degrading fibrinogen, prothrombin and FVIII. Lumbrokinase can reduce fibrinogen content, shorten euglobulin dissolution time, reduce whole blood viscosity and plasma viscosity, increase t-PA (tissue plasminogen activator) activity, and reduce plasminogen activator inhibition activity, increase fibrin degradation products, etc.
Lumbrokinase has been proven to have good clinical application value. It is a multi-molecule recombinant oral preparation that has special affinity with thrombus (fibrin). It can track thrombolysis, effectively dissolve microemboli, improve microcirculation, and strengthen the heart. , Cerebrovascular collateral circulation, open repair of damaged endothelial cells of blood vessels, increase blood vessel elasticity, improve blood vessel oxygen supply function, reduce blood viscosity, reduce platelet aggregation rate, inhibit re-formation of thrombus. Repair peripheral necrotic brain cells after thrombosis and save the penumbra. It has been widely used in clinical practice and is increasingly used in prevention and treatment centers for cardiovascular, cerebrovascular, endocrine, respiratory and other diseases.
Joyous Lumbrukinase powder specification

Terms	Standard	Terms	Standard
Product Name	Lumbrukinase	Appearance	White Powder
Purity	99%	Loss on Drying	≤8%
Total Heavy Metals	≤10 ppm	Ash	≤1%
As	≤0.5ppm	Total Plate Count	≤1000 cfu/g
Pb	≤0.5ppm	Yeast and Mold	≤100 cfu/g
Cd	≤0.5ppm	Coliforms	Negative
Hg	≤0.1ppm	E.Coli	Negative
Packing	Pack in 25kgs paper-drums, inner by double plastic bag	Shelf life	24 months under the above condition, and in its original package

Lumbrukinase Efficacy and Pharmacokinetics
After intravenous injection of 125I-labeled lumbrokinase, the blood concentration in the body is close to zero after 6 hours, and the instantaneous urine excretion measurement is close to zero after 18 hours. Even a large dose will not stay in the body for more than 24 hours. It shows that long-term use will not accumulate in the body. Lumbrokinase is easily absorbed after oral administration and can exert its pharmacological effects 40 to 80 minutes after taking the drug. Its half-life is 1.5 to 2.5 hours.

1. Coronary heart disease
t-PA and PAI are a pair of biological regulatory factors mainly synthesized and secreted by vascular endothelial cells, which are of great significance to the function of the fiber maintenance fibrinolytic system. t-PA can specifically bind to fibrin in thrombus and has selective thrombolytic effect. PAI is a rapid inhibitor that can irreversibly bind to t-PA and urokinase to inactivate them. It can also inhibit the action of urokinase and play a decisive role in regulating the fibrinolytic system. It increases PAI activity in patients with coronary heart disease and inhibits t-PA activity, resulting in low fibrinolysis. Urokinase mainly activates plasminogen in plasma and converts it into plasmin with thrombolytic activity, thereby degrading fibrinogen and fibrin clots and dissolving the thrombus. Lumbrokinase can also directly dissolve fibrin. Studies have shown that the plasma t-PA activity of patients in the AMI group increased significantly after 12 hours of treatment. On the 3rd day, the difference from before treatment was still significant, and it was not until the 7th day that it gradually returned to the original level. After 5 days of lumbrokinase treatment, the function of the fibrinolytic system can be significantly improved. Therefore, urokinase thrombolysis and oral administration of lumbrokinase will help improve the function of the patient's fibrinolytic system and reduce the occurrence of reinfarction after thrombolysis.
2. Cerebral infarction
Cerebral infarction is the most common cerebrovascular disease, accounting for about 50% to 60% of cerebrovascular diseases. Stroke has become the main cause of death in middle-aged and elderly people in many countries. Ischemic stroke accounts for 60% to 80% of the total stroke incidence, and the disability rate is very high. In the acute stage of cerebral infarction, measures such as controlling cerebral edema, increasing cerebral blood flow and brain tissue oxygen saturation are definitely beneficial to patients. Clinical observation shows that 665 patients with cerebral infarction were treated with lumbrokinase capsules orally for 15 to 28 days, with a significant efficiency of 60.94% to 73.66% and a total effective rate of 88.0% to 98.88%. The embolization volume was significantly reduced in 98.6% of patients, and the average reduction rate of embolization volume was 74.1%. The improvement rate of mouth and eye deviation and limb numbness after taking the medicine for 3 to 5 days accounted for 79.85%. After treatment, the improvement rate of dizziness and headache in patients was 95.95%. The improvement rate of tongue stiffness and speech obstruction was 94.7%, the improvement rate of mouth and eye distortion was 91.3%, the improvement rate of hemiplegia was 92.3%, the improvement rate of limb numbness was 92.9%, and the improvement rate of twitchiness in the hands and feet was 85.7%. Clinical studies have confirmed that lumbrokinase has a special affinity with fibrin, does not affect the normal coagulation system function of the body, and can significantly reduce the scope of the ischemic penumbra. The use of lumbrokinase in the treatment of cerebral infarction has a significant effect on the recovery of paralyzed limbs of patients. It can effectively improve the clinical symptoms and signs of patients with cerebral infarction, reduce the patient's disability rate, and has mild sequelae. The effective rate and effective rate are significantly better than those of the antimicrobial drug The recurrence rate of thrombozyme and Xueshuo Xinmaining is significantly lower than that of common aspirin therapy and ticlopidine hydrochloride and other drugs. They have mild side effects and are ideal oral anti-thrombolytic drugs with similar t-PA effects for the prevention and treatment of cerebral infarction. .
3. Diabetes
Plasma GMP140 is one of the products released by activation of platelets or endothelial cells. Studies have shown that the measurement of GMP140 content in plasma can also reflect the degree of activation and thrombosis tendency of platelets in the body, while TXB2 is the metabolic end product of XA2, which has a strong Promotes platelet aggregation and vasoconstriction. Many reports show that plasma GMP140 and TXB2 levels in diabetic patients are significantly increased, indicating that platelets in diabetic patients are in an activated state. Increased platelet adhesion and aggregation function is one of the reasons why diabetic patients develop early and high incidence of arteriosclerosis and are prone to microvascular disease. Lumbrokinase is a group of acidic proteins extracted from artificially raised earthworms. Plasma TXB2 levels in diabetic patients dropped significantly after oral administration of lumbrokinase for 2 weeks, and were not significantly different from the control group, suggesting that lumbrokinase has a significant inhibitory effect on platelet adhesion and aggregation. Plasma GMP140 levels also decreased significantly after treatment, indicating that lumbrokinase can inhibit platelet activation in diabetic patients to a certain extent.
4. Nephrotic syndrome
Lumbrokinase is a group of proteolytic enzymes extracted from special earthworms. In 1984, preliminary research results from Tsinghua University and other institutions showed that lumbrokinase has thrombolytic, anticoagulant and defibrillating effects. Its mechanism of action has been confirmed so far. First, it has the effect of plasminogen activator (similar to t-PA); second, it binds to fibrin to rapidly degrade fibrin. It has direct and indirect thrombolytic functions. Patients with nephrotic syndrome often have increased coagulation activity of the internal coagulation system. Increased fibrinogen promotes blood coagulation and promotes the formation of microthrombi in the glomerular capillaries. Most patients with NS are in a hypercoagulable state and have a tendency to form thrombosis. The research results of Hou Ming and others from the Affiliated Hospital of Shandong Medical University have shown that the decrease in fibrinolytic kinase activity (mainly t-PA) and the increase in fibrinolytic inhibitory activity (mainly a2-PA) are responsible for the formation and progression of blood hypercoagulability in chronic glomerular diseases. One of the important reasons. The experimental examination of this group showed that the blood fibrinogen and blood viscosity indicators were significantly increased, which is basically consistent with the reports of some domestic scholars. It is assumed that the effect of this group's use of lumbrokinase to treat PNS is to supplement or increase the content of t-PA in the blood, thereby rebalancing the imbalance between activation and inhibitory factors in the blood fibrinolytic system during NS, and acting as an anticoagulant and Thrombolysis improves glomerular microcirculation, thereby reducing urinary protein and improving renal function. In 1983, Mihara Tsune of Miyazaki University in Japan used earthworm extract to clinically treat thousands of cases of thromboembolic diseases, with an effective rate of over 80%. In 1993, Zhu Changlian et al. reported 9 cases of primary glomerular disease. The 24-hour urinary protein quantification after oral administration of lumbrokinase extract was significantly reduced compared with before treatment. 2 cases of renal insufficiency were significantly improved after lumbrokinase treatment. The therapeutic effects are encouraging. The total effective rate of 20 cases of PNS in this group after treatment was 95%, which was significantly higher than the 65% in the control group, with a significant difference at P<0.05. The difference in efficacy between type Ⅰ and type Ⅱ may be related to the long course of the disease, the severe degree of renal damage, and the different pathological types. Due to various reasons, the relationship between pathological classification and efficacy has not been studied, and further exploration is needed.
5. Cor pulmonale
Clinical studies of lumbrokinase on cor pulmonale have confirmed that patients' blood rheology indicators have changed significantly, clinical symptoms have improved, and the total effective rate of treatment is 88.4%. Examination of the patient's nail fold microcirculation has shown that the red blood cells aggregated and the blood color darkened before treatment. The redness was improved, the oxygen content in the patient's body increased, chest tightness and shortness of breath were alleviated, and no adverse reactions occurred. It is a safe and effective anti-thrombolytic drug for the treatment of pulmonary heart disease.
6. Deep vein thrombosis of lower limbs
Deep vein thrombosis of the lower limbs is considered acute if it occurs within 3 to 7 days, and chronic if it occurs for more than 7 days. In acute cases, thrombolytic treatment such as urokinase is effective, but in chronic cases, it is basically ineffective. Chronic deep vein thrombosis is a common clinical condition and there is no ideal treatment. Simply taking 2 pills of lumbrokinase tid for 21 days showed that the total effective rate for deep vein thrombosis of the lower limbs was 79.99%, with a significant effect of 28.57%. The total effective rate is close to the subcutaneous injection of small molecule heparin (82.20%). Lumbrokinase is effective.
Package and delivery

Delivery
1-80kg	80-300kg	More than 300kg
More suitable for express transportation, door-to-door	More suitable for air transportation,airport-to-airport	More suitable for ocean transportation,port-to-port
7-10 days for delivery time	3-4 days for delivery time	20-40 days for delivery time

What service we can provide
Joyous Health provides Lumbrukinase powder OEM services. We can customize formulas for customers, private labels, capsules, tablets, soft capsules, sachets, and PQQ pellets with low MOQ, which is suitable for direct sales by brands. Our OEM product shipping channels are stable and delivery times are fast and worthy of customers' trust, we have served more than 300 brands.

Joyous Health Factory information and certifications
Xi'an Joyous Health Biotechnology Co., Ltd. was established in 2011. Over the past 12 years, Joyous Health has obtained ISO 9001, FDA, ISO 22000, and GMP certifications.
Joyous Health has an advanced laboratory to control quality, so that each batch of products undergoes strict testing, and has professional R&D personnel to provide customized product services.
For more details please click here

Where to buy Lumbrukinase powder?
We offer the best Lumbrukinase powder at the most competitive price. Lumbrukinase Powder bulk and wholesale powder have been 3rd lab-tested and verified for both product purity and identity.
We also provide Lumbrukinase powder in bulk order or wholesale according to client needs. Just submit the requirements in the bottom form, and we will reply soon!

Contacts: Faith Feng
Email:faith@joyouspellets.com
Tel and Whatsapp:+86 17391747738

REQUEST MORE DETAILS

Please fill out the form below and click the button to request more information about

We provide high-quality products and services, as well as customized pellets. We are a professional ingredient supplier and solution provider.

Contact: Xi'an international enterprise center B building, Fengcheng 4 road, Xi'an City, Shaanxi province, China; info@joyouspellets.com; +86 17391747738

Follow Us

Lates News: Don't miss our news subscription, please fill in the form below.

Leave Message

FirstName*

LastName*

Email*

Tel No.

Message

オンライン体験を向上させるために Cookie を使用します。この Web サイトの閲覧を続けると、Cookie の使用に同意したものとみなされます。